

COVID-19

SARS-CoV-2 Spike protein related products



SARS-COV2 S1RBD-ACE2 Binding Assay (Cat No:41A249R)



SARS-COV2 virus enters human epithelial cells by the interaction between the receptor-binding domain of spike protein (S1RBD) on the surface of the viral particle and the ACE2 receptor on the surface of human cells. The S1RBD-ACE2 interaction is the crucial step of COVID-19 infection, and is therefore the principal target for development of vaccines and drugs against COVID-19. **SARS-COV2 S1RBD-ACE2 Binding Assay** can characterize the binding affinity of S1RBD-ACE2 receptor complex in the presence of potential inhibitors or neutralizing antibodies in a simple and sensitive manner.

This assay can be used for:

- **1. Measurement of circulating neutralizing antibody level in COVID-19 patients;**
- **2. Evaluation of dynamic changes in circulating neutralizing antibody level after vaccination;**
- **3. High throughput screening and validation of therapeutic compounds/antibodies targeting the S1RBD-ACE2 complex.**

Assay principle:

Representative data:



Website: www.torontobioscience.com

Brett Wang

Covid-19 Business Development Manager

brett.wang@torontobioscience.com

or sales@torontobioscience.com

Tel: (+1) 416 417 8573